Literature DB >> 33748880

Self-medication with herbal medicine and breast cancer survival: a prospective monocentric study.

Wala Ben Kridis1, Ahmed Mnif2, Souhir Khmiri2, Nabil Toumi2, Afef Khanfir2.   

Abstract

PURPOSE: The use of complementary and alternative medicine (CAM) is common among breast cancer patients, but less is known about whether CAM influences breast cancer survival. The primary aim of this study was to determine the impact of self-use of herbs on the overall survival.
METHODS: This was a prospective study including 110 patients with breast cancer. All patients were questioned about the concept of taking herbs. We analyzed the demographic data and the overall survival.
RESULTS: The average age was 51 years (30-80 years old). 37 had metastatic disease (33.6%). 48 patients had taken plants (43.6%). 19 patients consumed Graviola (39.6%) and 29 Alenda (60.4%). Overall survival at 3 years and at 5 years were, respectively, 96.2% and 82.4% in the absence of plant consumption versus 78.5% and 78.5% in case of plant consumption (p = 0.015).
CONCLUSION: This study concluded that self-medication with Graviola or Alenda may be associated with an increase of death risk in patients with breast cancer. Further studies are needed to confirm these results.

Entities:  

Keywords:  Alternative medicine; Breast cancer; Complementary medicines; Interaction; Neoplasm; Phytotherapy; Survival

Year:  2021        PMID: 33748880     DOI: 10.1007/s00432-021-03600-y

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  2 in total

Review 1.  Complementary and alternative medicine use among women with breast cancer.

Authors:  Lisa M DiGianni; Judy E Garber; Eric P Winer
Journal:  J Clin Oncol       Date:  2002-09-15       Impact factor: 44.544

2.  User rate of complementary and alternative medicine (CAM) of patients visiting a counseling facility for CAM of a German comprehensive cancer center.

Authors:  Jutta Huebner; Oliver Micke; Ralph Muecke; Jens Buentzel; Franz Josef Prott; Ulrich Kleeberg; Bianca Senf; Karsten Muenstedt
Journal:  Anticancer Res       Date:  2014-02       Impact factor: 2.480

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.